ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSpese di vendita, generali e amministrative1.37 B948.1 M928.7 M886.6 M1.03 B928.8 M3.77 BRicerca e sviluppo—222 M218.8 M250.4 M—248.6 M—Reddito operativo-179.8 M-2.88 B233 M178.8 M-192.7 M-79.7 M139.4 MProventi non operativi, Totale-226.5 M-99.3 M-333.5 M-67.1 M-30.7 M-47.5 M-478.8 MOneri finanziari, al netto degli interessi capitalizzati120.2 M115.5 M116.6 M119.6 M119.6 M120.1 M475.9 MProventi non operativi, esclusi gli oneri finanziari-120.2 M-115.5 M-116.6 M-119.6 M-119.6 M-120.1 M-475.9 MEntrate/uscite straordinarie-226.5 M-99.3 M-333.5 M-67.1 M-30.7 M-47.5 M-478.8 MUtile al lordo delle imposte-526.5 M-3.1 B-217.1 M-7.9 M-343 M-247.3 M-815.3 MQuota di utile———————Imposte-10 M-55 M-212.5 M120.3 M-2.9 M-423.7 M-518.8 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte-478.3 M-203.8 M-522.5 M-109.5 M-133.5 M-182.3 M-947.8 MUtile netto al lordo delle attività cessate-516.5 M-3.04 B-4.6 M-128.2 M-340.1 M176.4 M-296.5 MAttività cessate———————Utile netto-516.5 M-3.04 B-4.6 M-128.2 M-340.1 M176.4 M-296.5 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-516.5 M-3.04 B-4.6 M-128.2 M-340.1 M176.4 M-296.5 MUtile base per azione (EPS base)-0.44-2.550-0.11-0.340.15-0.3Utile diluito per azione (EPS diluito)-0.43-2.550-0.11-0.340.15-0.3Numero medio di azioni ordinarie in circolazione1.21 B1.19 B1.17 B1.16 B1.2 B1.16 B—Azioni diluite in circolazione01.19 B1.17 B1.16 B01.18 B—EBITDA566.4 M-2.22 B911.3 M867.3 M574.1 M596.4 M2.95 BEBIT-179.8 M-2.88 B233 M178.8 M-192.7 M-79.7 M139.4 MCosto del fatturato2.31 B2.09 B2.25 B2.39 B2.56 B2.36 B9.55 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)746.2 M664.7 M678.3 M688.5 M766.8 M676.1 M2.81 B
Viatris Inc. - Common Stock
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.
Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue.